CliffBio
biologic

Vyepti

eptinezumab-jjmr

Loss of exclusivityFebruary 2032projected — 12-year biologic exclusivity estimate
CompanyLundbeck Seattle BioPharmaceuticals, Inc.

Drug detail

Brand nameVyepti
Active ingredienteptinezumab-jjmr
Strength100MG/ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2020
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Vyepti patent cliff — loss of exclusivity February 2032 | CliffBio